書誌事項
- タイトル別名
-
- Clinical Study of Tongue Cancer
- トウ カ ニ オケル ゼツガン ノ リンショウテキ ケントウ
この論文をさがす
抄録
<p>Surgical resection is the standard treatment for tongue cancer. We conducted a retrospective investigation of the clinical outcomes of 202 patients with tongue cancer who were treated surgically at our institution.</p><p>The 5-year overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) rates in the overall subject population (n = 202) were 72%, 54%, and 78%, respectively.</p><p>The 5-year OS rates were 90%, 75%, 61%, and 46% in patients with T1, T2, T3, and T4 tumors, respectively. The 5-year DFS rates were 72%, 47%, 52%, and 41% in patients with T1, T2, T3, and T4 tumors, respectively. The 5-year DSS rates were 93%, 84%, 68%, and 49% in patients with T1, T2, T3, and T4 tumors, respectively.</p><p>The 5-year OS rates were 90%, 72%, 71%, and 53% in the patients classified as having Stage I, Stage II, Stage III, and Stage IV disease, respectively. The 5-year DFS rates were 71%, 45%, 63%, and 45% in the patients classified as having Stage I, Stage II, Stage III, and Stage IV disease, respectively. The 5-year DSS rates were 93%, 82%, 71%, and 61% in the patients classified as having Stage I, Stage II, Stage III, and Stage IV disease, respectively.</p><p>In patients with locally advanced disease (high T stage), the treatment outcomes were unsatisfactory. Therefore, further prospective analyses are recommended to improve the prognosis in patients with tongue cancer treated by surgery.</p>
収録刊行物
-
- 耳鼻咽喉科臨床 補冊
-
耳鼻咽喉科臨床 補冊 163 (0), 59-65, 2023
耳鼻咽喉科臨床学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390298975420131584
-
- NII書誌ID
- AN10020883
-
- ISSN
- 21851557
- 09121870
-
- NDL書誌ID
- 033149769
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDL
- Crossref
-
- 抄録ライセンスフラグ
- 使用不可